Omnicell Gestion
Gestion contrôle des critères 3/4
Le PDG Omnicell est Randy Lipps, nommé en Sep1992, a un mandat de 33.75 ans. La rémunération annuelle totale est $ 7.53M, composée du salaire de 11.2% et des bonus 88.8%, y compris les actions et options de la société. détient directement 1.95% des actions de la société, d'une valeur de $ 37.21M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.3 ans et 7.1 ans.
Informations clés
Randy Lipps
Directeur général
US$7.5m
Rémunération totale
| Pourcentage du salaire du PDG | 11.24% |
| Durée du mandat du directeur général | 33.8yrs |
| Propriété du PDG | 2.0% |
| Durée moyenne d'occupation des postes de direction | 3.3yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 7.1yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • Jun 04
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Demand
Analysts have lifted their price target on Omnicell by $12 in total, supported by refreshed assumptions on discount rate, revenue growth, profit margin and future P/E. These changes leave the stock's fair value estimate broadly unchanged at about $61.29.Mise à jour du récit • May 19
OMCL: Cabinet Replacement Cycle Will Support Stronger Future Medication Management Upside
Analysts lifted the Omnicell price target by about $4, reflecting updated fair value estimates and revised assumptions on discount rate, revenue growth, profit margin, and future P/E multiples, supported by recent research from multiple firms. Analyst Commentary Recent Street research includes price target increases of about $2 and $10, which gives a sense of how bullish and cautious views are being weighed around Omnicell right now.Article d’analyse • May 14
Omnicell's (NASDAQ:OMCL) Conservative Accounting Might Explain Soft Earnings
The market was pleased with the recent earnings report from Omnicell, Inc. ( NASDAQ:OMCL ), despite the profit numbers...
Mise à jour du récit • May 01
OMCL: New Product Cycle Will Reset Expectations And Support Higher Future Earnings Multiple
Analysts have reset their view on Omnicell, with the consolidated fair value estimate moving from $49.00 to $55.00. This reflects updated assumptions on discount rate, growth, margins and future P/E, alongside recent price target hikes and rating changes across the Street.Mise à jour du récit • Apr 16
OMCL: New Product Cycle Will Drive Next Cabinet Super Cycle
Narrative Update on Omnicell Analysts now see a slightly lower blended price target for Omnicell, with recent moves spanning a $14 cut at one firm and a $10 increase at another. They are weighing a new product cycle against differing views on execution and risk.Mise à jour du récit • Apr 01
OMCL: Cabinet Replacement Cycle Will Drive Future Super Cycle Repricing
Narrative Update on Omnicell The updated analyst price target for Omnicell has shifted by $14 as analysts balance recent upgrades tied to a new product cycle and cabinet replacement opportunity against a lower target from one firm, while keeping the model's fair value estimate steady at $49. Analyst Commentary Recent research on Omnicell presents a mixed picture, with some firms highlighting upside linked to a new product cycle and cabinet replacement opportunity, while more cautious voices are resetting expectations and price targets.Mise à jour du récit • Mar 18
OMCL: Cabinet Replacement Cycle Will Drive Future Risk Reward Repricing
Analysts have trimmed the Omnicell fair value estimate from $50.00 to $49.00, reflecting slightly softer assumptions for revenue growth and profit margins, even as they factor in a higher future P/E multiple supported by recent upgrades tied to the new product cycle and cabinet refresh story. Analyst Commentary Recent Street research on Omnicell has been mixed, with some firms trimming price targets while others turn more constructive on the new product cycle and cabinet refresh opportunity.Mise à jour du récit • Mar 04
OMCL: Cabinet Replacement Cycle Will Drive Future Medication Management Upside
Analysts have adjusted their Omnicell price target by $14, reflecting mixed research that includes both target cuts and upgrades related to expectations around the new product cycle and potential cabinet replacement demand. Analyst Commentary Bullish Takeaways Bullish analysts see the new Titan XT cabinets as a key product that could support higher long term growth expectations if hospitals move ahead with planned cabinet replacements.Mise à jour du récit • Feb 18
OMCL: Cabinet Refresh Cycle Will Support Future Medication Management Upside
Analysts have nudged their fair value estimate for Omnicell higher from $51.50 to about $57.43, citing updated views on its product cycle and cabinet refresh opportunity as reflected in recent research. Analyst Commentary Recent research coverage on Omnicell reflects a mix of optimism around the new product cycle and cabinet refresh, alongside some restraint on how quickly that opportunity may translate into value.Article d’analyse • Feb 12
Why Investors Shouldn't Be Surprised By Omnicell, Inc.'s (NASDAQ:OMCL) 26% Share Price Plunge
The Omnicell, Inc. ( NASDAQ:OMCL ) share price has softened a substantial 26% over the previous 30 days, handing back...
Mise à jour du récit • Feb 04
OMCL: Cabinet Replacement Cycle Could Drive Upside In Concentrated Market
Analysts have raised their fair value estimate for Omnicell to US$63 from US$55, citing updated assumptions for revenue growth, profit margins, and a lower future P/E multiple. This change is supported by recent positive research on the potential impact of the Titan XT cabinet cycle and competitive wins.Mise à jour du récit • Jan 21
OMCL: Cabinet Replacement Cycle Will Shape Future Risk Reward Balance
Narrative Update on Omnicell The analyst price target for Omnicell has moved from $43 to $50 as analysts point to potential cabinet replacement demand and the Titan XT launch as key drivers for expected improvements in sales, earnings, and valuation assumptions. Analyst Commentary Recent research highlights a more constructive tone around Omnicell, with some analysts pointing to a potential cabinet replacement cycle and the Titan XT launch as key themes in their work.Mise à jour du récit • Jan 06
OMCL: Future Medication Management Platform Rollout Will Support Balanced Risk Reward Profile
Analysts have lifted their price target on Omnicell from US$34 to US$43, pointing to updated assumptions for slightly lower discount rates, firmer revenue growth, improved profit margins, and a more moderate future P/E outlook. What's in the News Omnicell launched Omnicell Titan XT, an enterprise version of its automated dispensing systems designed to unify automation with its cloud-based OmniSphere medication management platform, aiming to create a connected, enterprise-wide medication management ecosystem across care areas.Mise à jour du récit • Dec 18
OMCL: New Medication Management Platform Will Support Future Upside Potential
Analysts have raised their price target on Omnicell from approximately 47.33 dollars to 51.50 dollars. This change reflects slightly lower perceived risk, modestly stronger long term profit margins, and a higher expected future earnings multiple.Mise à jour du récit • Dec 04
OMCL: Share Repurchases Will Support Future Upside Potential
Analysts have modestly raised their price target on Omnicell to approximately $47.33 per share, reflecting slightly lower perceived risk and stable, long-term growth and profitability expectations. What's in the News Updated fourth quarter 2025 revenue guidance to a range of $306 million to $316 million, signaling stable near term demand (company guidance).Mise à jour du récit • Nov 20
OMCL: Share Repurchases And Executive Shifts Will Drive Future Upside
Analysts have revised their price target for Omnicell, lowering it modestly to $47.33 per share. This change reflects slight adjustments in key financial assumptions and uncertainty regarding future growth rates.Article d’analyse • Nov 13
Improved Revenues Required Before Omnicell, Inc. (NASDAQ:OMCL) Stock's 25% Jump Looks Justified
Omnicell, Inc. ( NASDAQ:OMCL ) shareholders would be excited to see that the share price has had a great month, posting...Mise à jour du récit • Nov 06
OMCL: Share Repurchases And Leadership Transition Will Strengthen Market Position
Omnicell's analyst price target has been raised from $44 to approximately $47.33 per share. Analysts cite improved outlooks for revenue growth, profit margins, and lower discount rates as reasons supporting the upward revision.Seeking Alpha • Jul 31
Omnicell Q2 Earnings: Market Ignoring The Segments
Summary Omnicell's service business is rapidly growing, now 22% of revenue, outpacing industry trends and supporting long-term upside. My updated DCF analysis yields a price target of $57.46, representing 93% upside, with Wall Street consensus trailing behind. The primary risk is the pace of transition from product to service revenue, but a strong backlog mitigates margin and cash flow concerns. Given robust service growth and healthy backlog, I maintain Omnicell at strong buy, seeing current volatility as a long-term buying opportunity. Read the full article on Seeking AlphaArticle d’analyse • Jul 16
Omnicell (NASDAQ:OMCL) May Have Issues Allocating Its Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. One common...Article d’analyse • Jun 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 27% Below Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Omnicell fair value estimate is US$40.16 Omnicell is estimated...Nouveau récit • May 27
Near-shoring And Digitization Will Drive Stability Despite Tariff Challenges
Supply chain improvements and near-shoring are expected to offset cost pressures, while a shift to recurring SaaS and services enhances earnings stability and valuation potential.Article d’analyse • May 14
It Looks Like Omnicell, Inc.'s (NASDAQ:OMCL) CEO May Expect Their Salary To Be Put Under The Microscope
Key Insights Omnicell's Annual General Meeting to take place on 21st of May CEO Randy Lipps' total compensation...Article d’analyse • May 09
US$38.50: That's What Analysts Think Omnicell, Inc. (NASDAQ:OMCL) Is Worth After Its Latest Results
There's been a notable change in appetite for Omnicell, Inc. ( NASDAQ:OMCL ) shares in the week since its first-quarter...Article d’analyse • Apr 07
Omnicell (NASDAQ:OMCL) Seems To Use Debt Rather Sparingly
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...Article d’analyse • Mar 20
Is Now An Opportune Moment To Examine Omnicell, Inc. (NASDAQ:OMCL)?
Omnicell, Inc. ( NASDAQ:OMCL ), is not the largest company out there, but it received a lot of attention from a...Article d’analyse • Feb 14
Why Omnicell's (NASDAQ:OMCL) Earnings Are Better Than They Seem
Despite posting healthy earnings, Omnicell, Inc.'s ( NASDAQ:OMCL ) stock has been quite weak. Our analysis suggests...Seeking Alpha • Feb 12
Omnicell Q4 Earnings: Ignore The Short-Term Noise
Summary Omnicell's Q4 2024 earnings showed strong service revenue growth, despite soft overall revenue guidance, highlighting the service business as the key value driver. My updated DCF analysis yields a price target of $64.05, representing a 54% upside, and I raise my rating from buy to strong buy. The service business has grown from 6% to 22% of revenue since 2020, outpacing industry growth and improving margins, indicating long-term value. Downside risks include the need to balance service growth with product decline, but the healthy backlog mitigates these concerns, presenting a buying opportunity. Read the full article on Seeking AlphaArticle d’analyse • Feb 09
Results: Omnicell, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
It's been a mediocre week for Omnicell, Inc. ( NASDAQ:OMCL ) shareholders, with the stock dropping 11% to US$40.16 in...Article d’analyse • Jan 28
Omnicell, Inc. (NASDAQ:OMCL) Shares Could Be 26% Below Their Intrinsic Value Estimate
Key Insights Omnicell's estimated fair value is US$59.79 based on 2 Stage Free Cash Flow to Equity Omnicell's US$44.35...Article d’analyse • Nov 27
Little Excitement Around Omnicell, Inc.'s (NASDAQ:OMCL) Revenues
With a price-to-sales (or "P/S") ratio of 2x Omnicell, Inc. ( NASDAQ:OMCL ) may be sending bullish signals at the...Article d’analyse • Nov 02
Omnicell, Inc. Just Beat EPS By 43%: Here's What Analysts Think Will Happen Next
Shareholders will be ecstatic, with their stake up 23% over the past week following Omnicell, Inc. 's ( NASDAQ:OMCL...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | US$20m |
| Dec 31 2025 | US$8m | US$847k | US$2m |
| Sep 30 2025 | n/a | n/a | US$20m |
| Jun 30 2025 | n/a | n/a | US$23m |
| Mar 31 2025 | n/a | n/a | US$21m |
| Dec 31 2024 | US$8m | US$822k | US$13m |
| Sep 30 2024 | n/a | n/a | -US$18m |
| Jun 30 2024 | n/a | n/a | -US$21m |
| Mar 31 2024 | n/a | n/a | -US$21m |
| Dec 31 2023 | US$11m | US$813k | -US$20m |
| Sep 30 2023 | n/a | n/a | -US$34m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$18m |
| Dec 31 2022 | US$8m | US$804k | US$6m |
| Sep 30 2022 | n/a | n/a | US$48m |
| Jun 30 2022 | n/a | n/a | US$61m |
| Mar 31 2022 | n/a | n/a | US$72m |
| Dec 31 2021 | US$8m | US$768k | US$78m |
| Sep 30 2021 | n/a | n/a | US$80m |
| Jun 30 2021 | n/a | n/a | US$60m |
| Mar 31 2021 | n/a | n/a | US$35m |
| Dec 31 2020 | US$8m | US$721k | US$32m |
| Sep 30 2020 | n/a | n/a | US$38m |
| Jun 30 2020 | n/a | n/a | US$49m |
| Mar 31 2020 | n/a | n/a | US$69m |
| Dec 31 2019 | US$7m | US$711k | US$61m |
Rémunération vs marché: La rémunération totale de Randy ($USD 7.53M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 5.30M ).
Rémunération et revenus: La rémunération de Randy a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Randy Lipps (69 yo)
33.8yrs
Titularisation
US$7,531,852
Compensation
Mr. Randall A. Lipps, also known as Randy, founded Omnicell, Inc. in September 1992 and has been its Chief Executive Officer and President since October 2002. Mr. Lipps has been Executive Chairman of Omnic...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 33.8yrs | US$7.53m | 1.95% $ 37.2m | |
| Executive VP & CFO | less than a year | US$1.51m | pas de données | |
| Executive VP & COO | 1.7yrs | US$4.01m | 0.026% $ 499.7k | |
| Executive VP | 5.2yrs | US$2.46m | 0.020% $ 374.3k | |
| VP, Chief Accounting Officer & Corporate Controller | 2.3yrs | pas de données | 0.0094% $ 180.1k | |
| Senior VP & CTO | 1.3yrs | pas de données | pas de données | |
| Senior VP & Chief Corporate Development Officer | no data | pas de données | pas de données | |
| Senior VP & Chief Marketing Officer | no data | pas de données | pas de données | |
| SVP & Chief People Officer | less than a year | pas de données | pas de données | |
| Senior VP & GM of International | 4.4yrs | pas de données | pas de données | |
| Senior Vice President of Quality & Product Regulatory | 4.4yrs | pas de données | pas de données | |
| Chief of Staff | 8.9yrs | pas de données | pas de données |
3.3yrs
Durée moyenne de l'emploi
52.5yo
Âge moyen
Gestion expérimentée: L'équipe de direction de OMCL est considérée comme expérimentée (ancienneté moyenne 3.3 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| Founder | 33.8yrs | US$7.53m | 1.95% $ 37.2m | |
| Independent Director | 2.4yrs | US$318.51k | 0.044% $ 839.4k | |
| Independent Director | 13.4yrs | US$322.37k | 0.15% $ 2.9m | |
| Independent Director | 7.3yrs | US$323.62k | 0.11% $ 2.2m | |
| Lead Independent Director | 12.4yrs | US$355.14k | 0.11% $ 2.1m | |
| Independent Director | 4.9yrs | US$303.23k | 0.050% $ 947.6k | |
| Independent Director | 7.1yrs | US$325.65k | 0.061% $ 1.2m | |
| Independent Director | 4.1yrs | US$330.14k | 0.049% $ 931.4k | |
| Independent Director | 2.9yrs | US$298.15k | 0.042% $ 802.2k |
7.1yrs
Durée moyenne de l'emploi
69yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de OMCL sont considérés comme expérimentés (ancienneté moyenne 7.1 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/06/09 09:26 |
| Cours de l'action en fin de journée | 2026/06/09 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Omnicell, Inc. est couverte par 19 analystes. 8 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Raymond Myers | Benchmark Company |
| William Sutherland | Benchmark Company |
| Zhilin Long | Berenberg |